Visunex Raises $20 Million in Series B Funding for Newborn Imaging Technology

May 12, 2017: By Jon Swedien

Vixunex logoVisunex Medical Systems, a manufacturer of advanced wireless, wide-field imaging systems for newborn infants, raised $20 million in a Series B funding, the Fremont, California, company announced May 5.

The firm introduced in 2016 the first wireless digital imaging platform for imaging the eye of neonatal and full term infants—the PanoCam LT.

“This new round of funding brings the total investment into Visunex Medical to $32 million and will allow the company to expand manufacturing operations to meet the market demand,” said Wei Su, PhD, Visunex’ founder and CEO.

Su said Visunex will also use the money to increase research and development.

Visunex said It will soon be adding a third imaging system to the PanoCam family, which currently consists of the LT and Pro wireless wide-field imaging systems. The new configuration is intended to expand the newborn and infant imaging market, the company said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022